CRDF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cardiff Oncology Inc (CRDF) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has a low price and analysts have a positive outlook with high price targets, the company's financial performance is weak, and there are no significant positive catalysts or trading signals. The technical indicators are mixed, and the options data does not show strong bullish sentiment. Holding off on investing until more positive catalysts or stronger financial performance is evident would be prudent.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 1.654), which may limit immediate upside potential.
Analysts have a positive outlook, with a $10-$12 price target and encouraging comments about the CRDF-004 trial results. The stock is trading at a low price, which some analysts see as an attractive entry point.
The company's financial performance is weak, with declining revenue, net income, and EPS in the latest quarter. There are no recent news events or significant trading trends from insiders or hedge funds. Congress trading data is also absent.
In Q3 2025, revenue dropped by -27.27% YoY, net income declined by -5.03% YoY, and EPS fell by -32.00% YoY. Gross margin remained at 100%, but the overall financial performance is weak.
Analysts are positive on the stock, with H.C. Wainwright maintaining a Buy rating and a $10 price target, and Noble Capital initiating coverage with an Outperform rating and a $12 price target. Both firms highlight the potential of Cardiff's lead program in metastatic colorectal cancer.
